Annual report pursuant to Section 13 and 15(d)

Consolidated Balance Sheets

v3.22.0.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Current Assets    
Cash and cash equivalents $ 67,325 $ 6,227
Prepaid expenses and other current assets 1,533 1,707
Total Current Assets 68,858 7,934
Property and equipment, net 101 174
Right of use asset 1,383 279
Deposits and other assets 23 23
Total Assets 70,365 8,410
Current Liabilities:    
Accounts payable 524 886
Accrued expenses 1,928 925
Accrued employee benefits 978 868
Lease liability 124 287
Total Current Liabilities 3,554 2,966
Lease liability - long term 1,403 186
Total Liabilities 4,957 3,152
Commitments and Contingencies
Series A Preferred Stock, $0.001 par value; 10,000,000 shares authorized; 0 and 120,000 issued and outstanding as of September 30, 2021 and December 31, 2020, respectively 0 12,798
Stockholders' Equity (Deficit):    
Series B Preferred Stock, $1,000 par value; 10,000,000 shares authorized, 0 issued and outstanding and 3,973 issued and outstanding as of September 30, 2021 and December 31, 2020, respectively 0 2,477
Common stock, $0.001 par value; 200,000,000 shares authorized, 132,044,866 issued and 132,042,538 outstanding at September 30, 2021 and 29,252,253 issued and 29,249,925 outstanding at December 31, 2020 132 29
Additional paid-in capital 336,560 240,821
Accumulated deficit (271,284) (248,094)
Total Synthetic Biologics, Inc. and Subsidiaries Equity (Deficit) 65,408 (4,767)
Non-controlling interest   (2,773)
Total Stockholders' Equity (Deficit) 65,408 (7,540)
Total Liabilities and Stockholders' Equity $ 70,365 $ 8,410